Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7258   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-000720-17
    Sponsor's Protocol Code Number:MOM-M281-006
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-09-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2019-000720-17
    A.3Full title of the trial
    Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia
    A.4.1Sponsor's protocol code numberMOM-M281-006
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development, LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen Research & Development, LLC
    B.5.2Functional name of contact pointClinical Registry Group
    B.5.3 Address:
    B.5.3.1Street Address920 US-202
    B.5.3.2Town/ cityRaritan
    B.5.3.3Post codeNJ 08869
    B.5.3.4CountryUnited States
    B.5.6E-mailJCI-Office@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNipocalimab
    D.3.2Product code M281
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.1CAS number 2211985-36-1
    D.3.9.2Current sponsor codeM281
    D.3.9.3Other descriptive nameNipocalimab
    D.3.9.4EV Substance CodeSUB182674
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNipocalimab
    D.3.2Product code M281
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.1CAS number 2211985-36-1
    D.3.9.2Current sponsor codeM281
    D.3.9.3Other descriptive nameNipocalimab
    D.3.9.4EV Substance CodeSUB182674
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adults with Warm Autoimmune Hemolytic Anemia
    E.1.1.1Medical condition in easily understood language
    Autoimmune Hemolytic Anemia
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10002285
    E.1.2Term Anemia hemolytic autoimmune (NOS)
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of nipocalimab in participants with warm autoimmune hemolytic anemia (wAIHA).
    E.2.2Secondary objectives of the trial
    The key secondary objectives of this study are to evaluate the:
    -Impact of nipocalimab treatment on fatigue
    -Impact of nipocalimab on corticosteroid use
    Other secondary objectives of this study are to evaluate the:
    -effects of nipocalimab on normalization of hemolytic markers
    -effects of nipocalimab on maintaining response in Hgb
    -effects of nipocalimab on normalization of hematologic and hemolytic parameters
    -effects of nipocalimab on the time to, and the duration of, Hgb response
    -impact of nipocalimab treatment on fatique improvement
    -effects of nipocalimab on health-related quality of life and health status
    -association between IgG reduction and Hgb/hemolysis parameters
    -impact of nipocalimab on the reduction of corticosteroid dose




    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Double blind period
    1.Participants ≥18 years of age.
    2.Diagnosed with active primary or secondary wAIHA, defined as:
    a.Hgb value<10 g / dl AND
    b.Signs of hemolysis, defined as: lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN), or haptoglobin below the lower limit of normal, or indirect bilirubin above the ULN AND
    c.Serological evidence of anti-erythrocyte antibodies associated with a DAT that is either positive for IgG only or is positive for IgG and C3d at screening. DAT: negative, can be repeated once. If negative, participant not eligible.
    3.Diagnosed with wAIHA for at least 3 months, and currently receiving or has previously received treatment for wAIHA (treatment naive participants not eligible)
    4.If on corticosteroids, participants must have been on treatment for at least 4 weeks with a stable dose during the screening period or for at least 14 days prior to randomization. whichever is longer. Note:
    Investigators can optimize the above background medications prior to randomization if they are following the above rules for stable dose duration.
    5.If receiving immunosuppressants, following drugs allowed: concomitant immunosuppressants are azathioprine, mycophenolate mofetil/mycophenolic acid, methotrexate, cyclosporine, tacrolimus, danazol, and cyclophosphamide. Participants on stable dose of these drugs for ≥12 weeks prior screening and during the screening period. If stopped, for at least 8 weeks prior to screening. Note: Investigators can optimize the above background medications prior to randomization if they are following the above rules for stable dose duration.
    6.Have a platelet count ≥30 × 10E9/L.
    7.Participants who have undergone splenectomy must be at least 3 months post resection prior to screening and must be vaccinated as per CDC annual Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States
    8.Participants with other autoimmune disease or lymphoproliferative disorders may be eligible if they are stable (no changes in concomitant disease-related medications and severity of disease for at least 3 months prior to screening). Participants with lymphoproliferative disease must have a low grade, be stable and be, unlikely to require chemotherapy or monoclonal antibody therapy during the double blind period of the study. Participants requiring change of treatment or new treatment for autoimmune or lymphoproliferative diseases (but not rescue therapy for wAIHA) during the DBP will be terminated from the study
    9.Have sufficient venous access to allow drug administration by IV infusion and blood sampling as per the protocol.
    10.Women of childbearing potential, defined as women physiologically capable of becoming pregnant, must have a negative serum pregnancy test at screening and a negative urine pregnancy test at Baseline. Menopausal women must have an elevated serum FSH level at Screening; if the FSH is not elevated, they are considered to be of childbearing potential and must have a negative serum pregnancy test at screening and a negative urine pregnancy test at Baseline to be eligible.
    11.Women of childbearing potential (incl. menopausal women who do not have elevated FSH) must agree to remain totally abstinent or to consistently use a reliable and highly effective method of contraception during the study and for 30 days after the last dose of study drug.
    12.Male participants must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for at least 90 days after receiving the last dose of study drug. In addition, male participants with partners who are a woman of childbearing potential are to be highly encouraged to inform their partner to use highly effective contraception methods that result in low failure rate (less than 1% per year)
    13. Participants who use herbal, naturopathic, traditional Chinese remedies, ayurvedic and nutritional supplements, or medical marijuana (with a doctor’s prescription) are eligible if the use of these medications is acceptable to the Investigator. These remedies must be at a stable dose and regimen using the same preparation for ≥2 months prior to Screening.
    14.Are able to understand and voluntarily provide written informed consent to participate in the study and comply with all study procedures. Patients who initially provide consent and subsequently withdraw it prior to randomization, will be deemed as having failed this inclusion criterion.
    15.Vaccinations prior to screening as per routine local guidelines (including COVID-19).
    Open-Label
    1.Have completed the DBL period (through Week 24), or have required rescue therapy at/or after Week 4 of the double-blind period, or failed to demonstrate an increase from baseline in Hgb of at least 1 g/dL and are symptomatic at or after Week 16 of the DBL period.
    2.Are able to understand and voluntarily provide written informed consent to participate in the OLE period and comply with all study procedures.
    E.4Principal exclusion criteria
    Double blind period
    1.Are currently taking IgG Fc-related protein therapeutics.
    2.Have received a transfusion within 30 days prior to randomization.
    3.Have any other associated cause of hereditary or acquired hemolytic anemia.
    4.Have received rituximab within 3 months prior to screening.
    5.Have received IVIg within 6 weeks prior to screening.
    6.Have been diagnosed with cold antibody AIHA, cold agglutinin syndrome, mixed type (ie, warm and cold) AIHA, or paroxysmal cold hemoglobinuria.
    7.Have a severe infection that requires parenteral anti-infectives and/or hospitalization, and/or is assessed as serious/clinically significant by the Investigator, within 8 weeks prior to screening. Any participant with an infection requiring oral anti-infectives within 4 weeks prior to screening will be excluded.
    8.Have a chronic infection or require chronic treatment with anti-infectives (eg, antibiotics, antivirals).
    9.Have received a live viral or bacterial vaccine within 4 weeks prior to first dose of study drug, or have a known need to receive a live viral or bacterial vaccine during the study or within at least 3 months after the last dose of study drug. For information regarding the Bacille Calmette-Guérin (BCG) vaccine, please see Exclusion Criterion 25.
    10.Have any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of their wAIHA, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant.
    11.Have any of the following viral testing outcomes: A history of HIV infection or positive test result for HIV-1 and HIV 2 antibodies; A positive test for hepatitis B virus surface antigen (HBsAg). For participants with a negative test for HBsAg along with a positive test for anti-hepatitis B core antibodies and a positive or negative test for anti-HBs antibodies, hepatitis B viral DNA detection will be performed. Participants with a positive hepatitis B viral DNA detection will be excluded. If HBV DNA testing cannot be performed, or there is evidence of chronic liver disease, the participant is not eligible for the protocol; A positive test for hepatitis C virus (HCV) unless 1 of the following conditions are met: (a) Has a history of successful treatment, defined as being negative for HCV RNA at least 24 weeks after completing antiviral treatment, and has a negative HCV RNA test result at least 24 weeks prior to screening and a negative HCV RNA test at the screening.
    12.Are currently breastfeeding, pregnant, intend to become pregnant during the study, or are planning egg donation during the study or within 30 days after the last dose of study drug.
    13.Have current alcohol/substance abuse/dependence, a history of alcohol/substance abuse/dependence within the 12 months prior to screening, or, in the Investigator's opinion, show evidence of ongoing alcohol/substance abuse/dependence.
    14.Are currently participating in another interventional clinical trial or have received any investigational drug within the past 3 months prior to screening.
    15.Have had any major surgery within 3 months prior to screening or have plans for or have been scheduled for any elective surgery or major dental procedure during the study.
    16.Have a history of a major organ transplant, or hematopoietic stem cell/marrow transplant.

    Further exclusion criteria listed in the protocol not listed here due to character restriction.

    Opel Label Extension
    1.Met any of the stopping criteria (see Section 6.4.1 of the protocol) or discontinued study drug during the DBP due to treatment-related AE.
    2.Currently have a serious or clinically significant infection requiring parenteral anti-infectives and/or hospitalization.
    The following exclusion criterion from the double-blind period also applies to enrollment in the OLE: Exclusion Criteria #8 and #21.
    Exception: Participants who were previously enrolled in this study and was unable to complete the DBP due to the Sponsor suspending dosing due to the COVID-19 pandemic can be enrolled in the OLE after meeting all of the double-blind eligibility criteria. Participants who completed the 28-week OLE before Amendment 6 can be re-enrolled in the OLE per investigator's discretion if the participants continue meet the eligibility criteria for the OLE. Participants will resuime study treatment calculated from the baseline visit once they have reconsented to the study.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is durable response in improvement of Hgb, defined as the attainment of the following at 3 consecutive visits (minimum duration 28 days), where at least the first is at or before Week 16, without the need of rescue therapy:
    • Hb concentration ≥10 g/dL AND
    • An increase from baseline in Hb ≥2 g/dL
    The first of the three consecutive visits must be at or before week 16 of the double-blind period in order to qualify for success in the primary efficacy endpoint. For example, if a participant attained the above criteria at weeks 18, 20, and 22 and not before, this participant would not be considered a success. If the participant attained the criteria at weeks 16, 18, and 20, the patient would be considered a success.

    Participants who took rescue therapy before reaching the criteria will be treated as having failed the primary efficacy outtome.
    If a participant has missing Hgb at both screening and baseline but is randomized by mistake, the participant will be excluded from the ITT analysis. This situation is unlikely to happen because the IVRS system requires screening Hgb for randomization to occur.

    E.5.1.1Timepoint(s) of evaluation of this end point
    The first of the three consecutive visits must be at or before week 16 in order to qualify for success in the primary efficacy endpoint.
    E.5.2Secondary end point(s)
    Key secondary endpoints:
    -Change in the level of participant fatigue. Change from baseline in the total score from the FACIT-Fatigue Scale at the time of durable response.
    -Change from baseline in the total score from the FACIT-Fatigue Scale at the end of the double-blind period (Week 24)
    -Percent reduction from baseline in average daily dose of prednisone or equivalent at Week 24 of the double-blind period among participants on prednisone or equivalent at baseline.
    Other Secondary Endpoints:
    -Normalization of hemolytic markers
    1. Proportion of participants who simultaneously attain normal lactate dehydrogenase (LDH), AND normal haptoglobin, AND normal indirect bilirubin levels at 3 consecutive visits.
    2. Attainment of a 2 g / dl Hgb increase from baseline AND normal LDH, and haptoglobin, and indirect bilirubin levels at any time during the study
    3. Attainment of a 2 g / dl Hgb increase from baseline AND normal LDH and, haptoglobin, and indirect bilirubin levels at 3 consecutive visits
    Normalization of hematologic and hemolytic parameters:
    -Hgb concentration, reticulocyte count, and hemolytic markers, and change from baseline in these parameters through Week 16 of the double-blind period
    -Hgb, reticulocyte count, and hemolytic markers, and change from baseline in these parameters through the study
    Effect of nipocalimab on maintaining response in Hgb
    -Proportion of participants wo achive the durable response in improvement of Hgb and maintain that response for up to 24 weeks throughout the study without the need of rescue therapy.
    -Time to and duration of Hgb response
    1. Time to response defined as the first time point at which the durable response criteria for the primary efficacy endpoint is met
    2. Duration from the first time point at which the durable Hgb response criteria for the primary efficacy endpoint is met until the time point at which it is no longer met
    -Change in the level of participant fatigue:
    Change from baseline in the total score, item scores and impact and experience domains from the FACIT-Fatigue Scale through Week 24 of the double-blind period
    -Changes in health-related quality of life parameters based on EQ-5D-5L, SF-36, PGIS, PGIC
    -Impact of nipocalimab on corticosterioid use
    Absolute reduction from baseline in average daily dose of prednisone or equivalent at Week 24 of the double-blind period amont all participants
    The proportion of participants who achieve corticosterioid reduction to ≤ 7.5 mg/day of oral prednisone (or equivalent) at Week 24 of double-blind period among participants on prednisone or equivalent >7.5 mg/day at baseline

    The proportion of participants who achieve the durable response in improvement of Hgb during the double-blind period and maintain that response for upt to 24 weeks throughout the study without the need of rescue therapy will be summarized descriptively.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The first of the three consecutive visits must be at or before week 16 in order to qualify for success in the primary efficacy endpoint.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability and Immunogenicity
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA73
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Ukraine
    Czechia
    France
    Germany
    Greece
    Hungary
    Israel
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 124
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 24
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 98
    F.4.2.2In the whole clinical trial 148
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care treatment is expected
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-09-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-03-31
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA